Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10586-10593

  Li, Zhuqing ^a   Mahesh, Sankaranarayana P ^a   Shen, De Fen ^a   Liu, Baoying ^a   Siu, Willie O ^a   Hwang, Frank S ^a   Wang, Qing Chen ^b   Chan, Chi Chao ^a   Pastan, Ira ^b   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MOLECULAR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER INVASION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OPHTHALMOSCOPY; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD22; B-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EYE NEOPLASMS; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL; MICE; MICE, SCID; NEOPLASM INVASIVENESS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4;

EID: 33751304461     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1981     Document Type: Article

References (35)

1. Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS, Jr., Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1988;62:2461-5.
2. Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193-202.
3. Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996;88:675-9.
4. Brain Tumor in the United States 1995-1999. Chicago (Illinois): Central Brain Tumor Registry of the United States, 2002-2003.
5. Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 2004;242:901-13.
6. Corriveau C, Easterbrook M, Payne D. Lymphoma simulating uveitis (masquerade syndrome). Can J Ophthalmol 1986;21:144-9.
7. Char DH, Ljung BM, Miller T, Phillips T. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 1988;95:625-30.
8. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999;106:1805-10.
9. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer 1993;72:843-9.
10. DeAngelis LM. Primary central nervous system lymphoma. Recent Results Cancer Res 1994;135:155-69.
11. Verbraeken HE, Hanssens M, Priem H, Lafaut BA, De Laey JJ. Ocular non-Hodgkin's lymphoma: a clinical study of nine cases. Br J Ophthalmol 1997;81:31-6.
12. Tuaillon N, Chan CC. Molecular analysis of primary central nervous system and primary intraocular lymphomas. Curr Mol Med 2001;1:259-72.
13. Chan CC. Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc 2003;101:275-92.
14. Chan CC, Fischette M, Shen D, Mahesh SP, Nussenblatt RB, Hochman J. Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2005;46:415-9.
15. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248:503-18.
16. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000;6:1476-87.
17. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7.
18. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11:1545-50.
19. Reiter Y, Brinkmann U, Jung SH, et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 1994;269:18327-31.
20. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5:2311-5.
21. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ, Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997;79:3409-13.
22. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol 2002;13:411-8.
23. Davis JL. Diagnosis of intraocular lymphoma. Ocul Immunol Inflamm 2004;12:7-16.
24. Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 2005;19:739-49.
25. Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 2001;13:137-42.
26. Fahim DK, Bucher R, Johnson MW. The elusive nature of primary intraocular lymphoma. J Neuro-ophthalmol 2005;25:33-6.
27. Kim SK, Chan CC, Wallace DJ. Management of primary intraocular lymphoma. Curr Oncol Rep 2005;7:74-9.
28. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997;115:1157-60.
29. Buggage RR, Whitcup SM, Nussenblatt RB, Chan CC. Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. Invest Ophthalmol Vis Sci 1999;40:2462-3.
30. Muller G, Hopken UE, Stein H, Lipp M. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leukoc Biol 2002;72:1-8.
31. Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004;76:462-71.
32. Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology 2003;110:421-6.
33. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003;101:815-21.
34. Streilein JW, Ma N, Hartmut H, Fong TF, Zamiri P. Immunobiology and privilege of neuronal retina and pigment epithelium transplants. Vision Res 2002;42:487-95.
35. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991;254:1173-7.